CV Sciences (CVSI) Cost of Revenue (2013 - 2026)
CV Sciences (CVSI) posted Cost of Revenue of $673000.0 for Q1 2026, down 86.26% sequentially from $4.9 million in Q4 2025, and down 7.93% YoY from $731000.0 in Q1 2025.
CV Sciences (CVSI) Cost of Revenue (2013 - 2026) Analysis & Trends
CV Sciences has reported Cost of Revenue for 14 years, with the latest figure at $673000.0 in Q1 2026.
- Quarterly Cost of Revenue fell 7.93% year-over-year to $673000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 30.94% YoY) and the FY2025 annual result came in at $7.0 million, down 17.57% from the prior year.
- Cost of Revenue slipped to $673000.0 in Q1 2026 per CVSI's latest filing, from $4.9 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $4.9 million in Q4 2025 and troughed at -$3.9 million in Q4 2023.
- A 5-year average of $1.6 million and a median of $2.2 million in 2022 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2023 and 2024: Cost of Revenue sank 269.92% in 2023, then surged 156.3% in 2024.
- Over 5 years, Cost of Revenue stood at $2.3 million in 2022, then tumbled by 269.92% to -$3.9 million in 2023, then soared by 156.3% to $2.2 million in 2024, then jumped by 121.88% to $4.9 million in 2025, then slumped by 86.26% to $673000.0 in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $673000.0, $4.9 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | CV Sciences | 4.12 Mn | 3.86 Mn | 1.45 Mn | 1.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Mn |
| Jun 30, 2026 | 1.54 Mn |
| Mar 31, 2026 | 673,000.00 |
| Mar 31, 2026 | 673,000.00 |
| Dec 31, 2025 | 4.90 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 371,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Mar 31, 2025 | 731,000.00 |
| Mar 31, 2025 | 731,000.00 |
| Dec 31, 2024 | 2.21 Mn |
| Dec 31, 2024 | 2.21 Mn |
| Sep 30, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.09 Mn |
| Jun 30, 2024 | 793,000.00 |
| Jun 30, 2024 | 793,000.00 |
| Mar 31, 2024 | 813,000.00 |
| Mar 31, 2024 | 813,000.00 |